Analysis-Most US companies seen sticking with quarterly reporting

The SEC is expected to seek comments on a proposal that could let U.S. public companies move from quarterly to semiannual earnings reporting, a change revived by President Trump. Investors and asset managers largely oppose the shift, warning it could raise volatility, hurt valuations, and increase the cost of capital, while smaller companies may be more receptive. JPMorgan said it would still provide quarterly guidance even if the rule changes.

Analysis

The market is likely to treat this as a governance/coverage event more than a fundamental earnings event. The first-order winner is not the companies that adopt semiannual reporting, but the intermediaries that can monetize the information vacuum: exchanges, index providers, and large-cap brokers with deeper private channels to management. For listed operating companies, the biggest second-order effect is a higher implied information risk premium, which should show up most clearly in smaller caps, lower-liquidity names, and firms already trading on thin analyst coverage.

The key dynamic is dispersion. Large, high-visibility names will probably keep quarterly cadence to protect valuation multiples, while optionality is greatest for smaller issuers that value cost savings over a 5-10% multiple haircut. That creates a potential bifurcation: companies with strong investor relations and recurring KPIs can absorb less frequent reporting, but businesses dependent on narrative trust, cyclical demand visibility, or complex accounting will be punished by a higher cost of capital. If adoption is sparse, the market may quickly move on; if even a handful of quality names opt in, the penalty could be front-loaded within weeks as PMs de-risk.

The contrarian view is that the headline policy change may ultimately be pro-market for the wrong names. Less frequent reporting could mechanically disadvantage long-only funds and favor faster, more alternative data-driven allocators who can use channel checks and private sourcing to build edge. That would compress the active-management advantage in traditional small-cap coverage and potentially accelerate consolidation toward larger platforms with better data infrastructure.

JPM and NDAQ are the cleanest relative winners: both benefit from a larger role in market infrastructure and investor communication regardless of reporting frequency. The risk is that the policy gets diluted into a voluntary regime that generates little adoption, in which case the trade becomes a fade of the whole theme rather than an earnings rerating story.

Key Decisions for Investors

• Long NDAQ vs. a basket of small-cap listed operating companies with weak coverage for 1-3 months; thesis is that exchanges monetize the governance shift while the covered cohort faces a multiple discount.
• Overweight JPM on a 4-8 week horizon as a relative-quality beneficiary; even if reporting norms loosen, high-visibility banks are most likely to preserve quarterly communication and retain valuation support.
• Short small-cap U.S. companies with low analyst coverage and weak liquidity if they announce a move to semiannual reporting; expect a 5-15% de-rating over days-to-weeks as PMs reduce position sizes.
• Avoid initiating new longs in subscale public biotech/small-cap growth names until reporting behavior becomes clear; these are the names most exposed to a higher information-risk premium.
• If adoption remains limited after the SEC comment process, fade the theme by trimming any NDAQ/JPM relative-overweight and rotating into quality small-cap names that explicitly commit to quarterly disclosure.